TORONTO, April 4 (Reuters) - Canadian pharmaceuticals company Atrium Innovations said on Friday it plans to sell its Active Ingredients and Specialty Chemicals division to Paris-based AXA Private Equity for $155 million as it shifts its focus to the health and nutrition segments of the market.
